




RealRate

PHARMACEUTICAL 2020

Aclaris Therapeutics Inc.
Rank 333 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 518% points.

The company's Economic Capital Ratio, given in the ranking table, is -913%, being 610% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	83,803
Cost of Goods Sold	4,055
Intangible Assets	7,199
Liabilities, Current	22,432
Liabilities, Non-Current	3,736
Other Assets	4,825
Other Compr. Net Income	3.0
Other Expenses	19,175
Other Liabilities	2,217
Other Net Income	-50,296
Property and Equipment	2,470
Research and Development	64,899
Revenues	4,227
Selling, General and Administrative Expense	27,156

Output Variable	Value in 1000 USD
Assets	98,297
Liabilities	28,385
Expenses	115,285
Stockholders Equity	69,912
Net Income	-161,354
Comprehensive Net Income	-161,352
Economic Capital Ratio	-913%